Todd R. Wiernicki

Figure 8B. [Carry-over from tips in (a) in subsequent plate (buffer addition only).].

Sitta Sittampalam, Kim E. Garbison, Beverly A. Heinz, 2012 .

Table 6: [Summary of modulators].

Sitta Sittampalam, Kim E. Garbison, Beverly A. Heinz, 2012 .

[Figure, Table 2. Typical FLIPR™ Assay Formats]

Sitta Sittampalam, Kim E. Garbison, Beverly A. Heinz, 2012 .

Inhibition of mitosis and microtubule function through direct tubulin binding by a novel antiproliferative naphthopyran LY290181.

Todd R. Wiernicki, D. Panda, M. Jordan, 1997, Molecular pharmacology.

An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis

Todd R. Wiernicki, Charles R. Yang, T. Suter, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Identification of Compounds with pH-Dependent Bactericidal Activity against Mycobacterium tuberculosis

Todd R. Wiernicki, P. Hipskind, C. Nathan, 2018, ACS infectious diseases.

ARL 17477, a selective nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia

Todd R. Wiernicki, M. O'Neill, D. Lodge, 2000, Brain Research.

Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: A Potential Novel Antipsychotic with Lower Histamine H1 Receptor Affinity Than Olanzapine

Todd R. Wiernicki, F. Bymaster, L. Nisenbaum, 2005, Journal of Pharmacology and Experimental Therapeutics.

Role of serine/threonine kinase casein kinase‐II in vascular smooth muscle cell proliferation and inhibition by heparin

Todd R. Wiernicki, J. Singh, T. Wiernicki, 1993 .